Your session is about to expire
← Back to Search
Bupivacaine for Postoperative Shoulder Pain
Study Summary
This trial is comparing pain scores and opioid use in patients receiving interscalene peripheral blocks with plain bupivacaine versus those receiving liposomal bupivacaine.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently receiving worker's compensation.You have been using opioid pain medication for a long time.My BMI is either below 18 or above 35.I am allergic to local anesthetics or painkillers.I am in good health and scheduled for elective shoulder surgery.I am medically cleared for elective shoulder surgery.I have kidney or liver problems.I am undergoing or have undergone a capsular release procedure.I am not pregnant, breastfeeding, or under 18.I do not speak English.I have trouble breathing.You smoke cigarettes.
- Group 1: Bupivacaine
- Group 2: Liposomal bupivacaine
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration accredited Bupivacaine liposome for medical use?
"Bupivacaine liposome has been approved for use, so its safety rating is 3."
Could you please elaborate on the past experiments conducted using Bupivacaine liposome?
"Presently, 18 trials for Bupivacaine liposome are in their third phase of testing with a total of 109 studies on the go. Although Philadelphia has the majority of these research projects, there are other sites across 144 locations also running experiments related to this medication."
Is this trial ongoing and presently open to participants?
"Affirmative, clinicaltrials.gov attests that this medical study is actively in search of participants. The trial was first listed on February 21st 2019 and its most recent update took place nearly two years later on September 27th 2021. Now, 80 people need to be enrolled from 1 site respectively."
For what medical indications is Bupivacaine liposome typically employed?
"Bupivacaine liposome is commonly used to manage pemphigus and has also been known to be effective in treating acute nonspecific tenosynovitis, general anesthesia, as well as lupus erythematosus cell."
What is the upper limit of individuals currently participating in this medical research?
"Affirmative, according to clinicaltrials.gov this medical trial is currently enrolling patients who meet certain criteria. The study was first made available on February 21st 2019 and the most recent modifications were done on September 27th 2021. 80 individuals are sought for participation at a single site."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- University of Southern California: < 24 hours
Share this study with friends
Copy Link
Messenger